These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9757854)

  • 1. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.
    Finkelstein JS; Klibanski A; Arnold AL; Toth TL; Hornstein MD; Neer RM
    JAMA; 1998 Sep 23-30; 280(12):1067-73. PubMed ID: 9757854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
    Finkelstein JS; Arnold AL
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
    Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
    N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
    Taga M; Minaguchi H
    Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
    Gallagher JC; Fowler SE; Detter JR; Sherman SS
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis.
    Newhall-Perry K; Holloway L; Osburn L; Monroe SE; Heinrichs L; Henzl M; Marcus R
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):824-9. PubMed ID: 7573251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
    Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
    Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nafarelin therapy in endometriosis: long-term effects on bone mineral density.
    Orwoll ES; Yuzpe AA; Burry KA; Heinrichs L; Buttram VC; Hornstein MD
    Am J Obstet Gynecol; 1994 Nov; 171(5):1221-5. PubMed ID: 7977523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).
    Adamson GD; Heinrichs WL; Henzl MR; Yuzpe AA; Bergquist C; Jacobson JJ; Eriksson S; Kwei L; Gilbert SM
    Am J Obstet Gynecol; 1997 Dec; 177(6):1413-8. PubMed ID: 9423744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density.
    Hornstein MD; Yuzpe AA; Burry K; Buttram VC; Heinrichs LR; Soderstrom RM; Steinberger E; Lin JS
    Fertil Steril; 1997 Jun; 67(6):1013-8. PubMed ID: 9176437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism.
    Gafni RI; Guthrie LC; Kelly MH; Brillante BA; Christie CM; Reynolds JC; Yovetich NA; James R; Collins MT
    J Bone Miner Res; 2015 Nov; 30(11):2112-8. PubMed ID: 25990370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
    DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
    Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study.
    Matsumoto T; Shiraki M; Hagino H; Iinuma H; Nakamura T
    Osteoporos Int; 2006 Oct; 17(10):1532-8. PubMed ID: 16767525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.
    Finkelstein JS; Hayes A; Hunzelman JL; Wyland JJ; Lee H; Neer RM
    N Engl J Med; 2003 Sep; 349(13):1216-26. PubMed ID: 14500805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
    J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gonadal suppression on the regulation of parathyroid hormone and 1,25-dihydroxyvitamin D secretion in women.
    Finkelstein JS; Schoenfeld DA
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2151-6. PubMed ID: 10372724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.